01 DEC 2003




FIG. 1A

01 DEC 2003




FIG. 1B



PBS
CTRL HAMSTER Ig
ANTI-α1
ANTI-α2
ANTI-α1 + α2
ANTI-α4
ANTI-α5
ANTI-α6
ANTI-β1
0
10
20
30
40
50
60
70
INCREASE IN FOOTPAD THICKNESS (%)

FIG. 2



PBS
CTRL HAMSTER Ig
CTRL RAT Ig
ANTI-ICAM-1
ANTI-α1
ANTI-α2
ANTI-α1 + α2
ANTI-α4
ANTI-α5
ANTI-α4 + α5
ANTI-α6
ANTI-β1
0
10
20
30
40
50
60
70
80
INCREASE IN EAR THICKNESS (%)

FIG. 3



INCREASE IN EAR THICKNESS (%)
0
10
20
30
40
50
60
70
80
WILD-TYPE MICE
PBS
CTRL HAMSTER Ig
ANTI-α1
ANTI-α2
ANTI-α1 + α2
α1-DEFICIENT MICE
PBS
CTRL HAMSTER Ig
ANTI-α2

FIG. 4



INCREASE IN EAR THICKNESS (%)
0
10
20
30
40
50
60
PBS
CTRL HAMSTER Ig
ANTI-α1
ANTI-α2
VEHICLE CTRL

FIG. 5



MEAN ARTHRITIC SCORE
16
12
8
4
0
PBS
CONTROL HAMSTER Ig
α1
α2
α1 + α2
mAb TREATMENT

FIG. 6




FIG. 7




FIG. 8A




FIG. 8B



MEAN ARTHRITIC SCORE
16
12
8
4
0
A
B
α1 +/+
α1 -/-
PBS
CTRL HAMSTER Ig
ANTI-α1
ANTI-α2
ANTI-α1 + α2
CTRL HUMAN Ig
mTNF-R55-Ig
ANTI-α4
ANTI-Mac-1
ANTI-ICAM-1
PBS
ANTI-α1
PBS
mAb TREATMENT

FIG. 9



FIG. 10



B6-129 Ha4/8 TREATED
B6-129 a1 TREATED
B6-129 Rag(-/-) Ha4/8 TREATED
B6-129 Rag(-/-) a1 TREATED
ARTHRITIC SCORE (MAX OF 4)
4
3.5
3
2.5
2
1.5
1
0.5
0
DAY 0
DAY 3
DAY 6
DAY 9
DAY 12
DAY 15

FIG. 11



Ha4/8 250 ug/MOUSE
a1 250 ug/MOUSE
a1 100 ug/MOUSE
a1 25 ug/MOUSE
a1 10 ug/MOUSE
ARTHRITIC SCORE (MAX OF 4)
4
3.5
3
2.5
2
1.5
1
0.5
0
DAY 0
DAY 3
DAY 6
DAY 9
DAY 12
DAY 15

FIG. 12



a1 DAY 0
Ha4/8 DAY 4
a1 DAY 4
hig DAY 4
TNF DAY 4
a1 + TNF DAY 4
ARTHRITIC SCORE (MAX OF 4)
0
0.5
1
1.5
2
2.5
3
3.5
4
DAY 0
DAY 3
DAY 6
DAY 9
DAY 12
DAY 15

FIG. 13

```
1   V S P T F Q V V N S F A P V Q E C S T Q
                      I
21  L D I V I V L D G S N S I Y P W E S V I
                                D       T
41  A F L N D L L K R M D I G P K Q T Q V G
61  I V Q Y G E N V T H E F N L N K Y S S T
81  E E V L V A A K K I G R Q G G L Q T M T
                      V Q R G G R
101 A L G I D T A R K E A F T E A R G A R R
          T
121 G V K K V M V I V T D G E S H D N Y R L
                                  H
141 K Q V I Q D C E D E N I Q R F S I A I L
      K
161 G H Y N R G N L S T E K F V E E I K S I
      S
181 A S E P T E K H F F N V S D E L A L V T
201 I V K A L G E R I F A L E A
        T
```

FIG. 14A




FIG. 14B

01 DEC 2003

1 V S P T F Q V V N S I A P V Q E C S T Q

21 L D I V I V L D G S N S I Y P W D S V T

41 A F L N D L L K R M D I G P K Q T Q V G

61 I V Q Y G E N V T H E F N L N K Y S S T

81 E E V L V A A K K I V Q R G G R Q T M T

101 A L G T D T A R K E A F T E A R G A R R

121 G V K K V M V I V T D G E S H D N H R L

141 K K V I Q D C E D E N I Q R F S I A I L

161 G S Y N R G N L S T E K F V E E I K S I

181 A S E P T E K H F F N V S D E L A L V T

201 I V K T L G E R I F A L E A

FIG. 15

FIG. 16A




FIG. 16B






FIG. 16C








FIG. 17B




FIG. 17A

0 1 DEC 2003




FIG. 18C




FIG. 18B




FIG. 18A